✦ LIBER ✦

Targeting PI3K/AKT Pathway is an Effective Strategy for the Treatment of Neuroendocrine Tumors Harboring PIK3CA Mutations

✍ Scribed by Jun Song; Jing Li; Ji Tae Kim; Heidi Weiss; Courtney M. Townsend; B.M. Evers

Book ID: 119432319
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 122 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(11)60472-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activation of the PI3K/AKT signalling pa

Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations

✍ Christian Hafner; Michael Landthaler; Thomas Vogt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB

Targeting the phosphatidylinositol 3-kin

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma

✍ Beck, Joseph Thaddeus; Ismail, Amen; Tolomeo, Christina 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 613 KB

FGFR1/PI3K/AKT signaling pathway is a no

FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug Fumagillin (TNP-470)

✍ Gregory J. Chen; Brian Weylie; Chen Hu; James Zhu; Reza Forough 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

## Abstract Fibroblast growth factor‐1 (FGF1), a prototypic member of the FGF family, is a potent angiogenic factor. Although FGF‐stimulated angiogenesis has been extensively studied, the molecular mechanisms regulating FGF1‐induced angiogenesis are poorly understood in vivo. Fumagillin, an antiang